See more : Retailors Ltd (RTALF) Income Statement Analysis – Financial Results
Complete financial analysis of Alar Pharmaceuticals Inc. (6785.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Alar Pharmaceuticals Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Pilgrim Petroleum Corporation (PGPM) Income Statement Analysis – Financial Results
- Greyson International, Inc. (GYSN) Income Statement Analysis – Financial Results
- Power Nickel Inc. (PNPNF) Income Statement Analysis – Financial Results
- Immo Lux – Airport S.A. (LUXA.BR) Income Statement Analysis – Financial Results
- Curzon Energy Plc (CZN.L) Income Statement Analysis – Financial Results
Alar Pharmaceuticals Inc. (6785.TWO)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.alarpharm.com
About Alar Pharmaceuticals Inc.
Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. It is developing ALA-1000, which is in Phase II clinical trials for the treatment of opioid use disorder; ALA-1300 and ALA-2000, which is in pre-clinical stage for opioid use disorder; ALA-4000 which is in pre-clinical stage for treatment of Parkinson's disease; and ALA-3000, which is in pre-clinical stage for treating treatment-resistant depression. Alar Pharmaceuticals Inc. was founded in 2016 and is based in Taichung, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 469.27M | 800.00K | 0.00 | 600.00K | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 3.15M |
| Gross Profit | 469.27M | 800.00K | 0.00 | 600.00K | -3.15M |
| Gross Profit Ratio | 100.00% | 100.00% | 0.00% | 100.00% | 0.00% |
| Research & Development | 56.71M | 34.18M | 81.89M | 160.33M | 55.19M |
| General & Administrative | 27.03M | 13.15M | 11.41M | 11.04M | 6.20M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 27.03M | 13.15M | 11.41M | 11.04M | 6.20M |
| Other Expenses | 0.00 | 9.55M | 27.52M | 26.28M | 0.00 |
| Operating Expenses | 83.75M | 47.33M | 93.30M | 171.37M | 61.39M |
| Cost & Expenses | 83.75M | 47.33M | 93.30M | 171.37M | 61.39M |
| Interest Income | 16.92M | 2.79M | 1.50M | 1.62M | 0.00 |
| Interest Expense | 63.00K | 22.00K | 21.00K | 33.00K | 0.00 |
| Depreciation & Amortization | 3.35M | 3.21M | 3.36M | 2.84M | 2.30M |
| EBITDA | 394.52M | -29.31M | -60.85M | -139.92M | -59.09M |
| EBITDA Ratio | 84.07% | -3,663.75% | 0.00% | -23,320.17% | 0.00% |
| Operating Income | 385.53M | -32.52M | -64.21M | -142.76M | -61.39M |
| Operating Income Ratio | 82.15% | -4,064.50% | 0.00% | -23,794.00% | 0.00% |
| Total Other Income/Expenses | 5.58M | 13.99M | 29.06M | 27.97M | -6.58M |
| Income Before Tax | 391.11M | -32.54M | -64.23M | -142.80M | -67.97M |
| Income Before Tax Ratio | 83.34% | -4,067.25% | 0.00% | -23,799.50% | 0.00% |
| Income Tax Expense | 8.49M | -12.67M | 0.00 | 0.00 | 0.00 |
| Net Income | 382.62M | -19.87M | -64.23M | -142.80M | -67.97M |
| Net Income Ratio | 81.53% | -2,483.88% | 0.00% | -23,799.50% | 0.00% |
| EPS | 6.71 | -0.35 | -1.13 | -2.86 | -1.94 |
| EPS Diluted | 6.71 | -0.35 | -1.13 | -2.86 | -1.94 |
| Weighted Avg Shares Out | 57.00M | 57.00M | 57.00M | 49.91M | 35.00M |
| Weighted Avg Shares Out (Dil) | 57.05M | 57.00M | 57.00M | 49.91M | 35.00M |
Source: https://incomestatements.info
Category: Stock Reports